Evolent Health, Inc. (NYSE:EVH) Stake Boosted by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC increased its stake in Evolent Health, Inc. (NYSE:EVH) by 602.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,042 shares of the technology company’s stock after purchasing an additional 5,182 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Evolent Health were worth $196,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. ICA Group Wealth Management LLC acquired a new stake in Evolent Health during the 4th quarter worth about $32,000. Hollencrest Capital Management acquired a new stake in Evolent Health during the 4th quarter worth about $42,000. Strs Ohio acquired a new stake in Evolent Health during the 1st quarter worth about $51,000. Van ECK Associates Corp acquired a new stake in Evolent Health during the 4th quarter worth about $54,000. Finally, Captrust Financial Advisors boosted its position in Evolent Health by 254.4% during the 2nd quarter. Captrust Financial Advisors now owns 1,758 shares of the technology company’s stock worth $54,000 after acquiring an additional 1,262 shares during the period.

Evolent Health Stock Down 0.0 %

EVH opened at $25.43 on Tuesday. The business has a 50 day moving average price of $28.83 and a 200 day moving average price of $31.30. Evolent Health, Inc. has a twelve month low of $21.83 and a twelve month high of $39.78. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.07 and a current ratio of 1.07. The firm has a market cap of $2.88 billion, a P/E ratio of -36.33 and a beta of 1.53.

Evolent Health (NYSE:EVH) last posted its earnings results on Wednesday, August 2nd. The technology company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.07. Evolent Health had a positive return on equity of 8.07% and a negative net margin of 3.89%. The firm had revenue of $469.14 million during the quarter, compared to analyst estimates of $462.51 million. Research analysts forecast that Evolent Health, Inc. will post 0.15 EPS for the current year.

Insiders Place Their Bets

In other Evolent Health news, President Daniel Joseph Mccarthy sold 1,000 shares of the business’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $31.44, for a total value of $31,440.00. Following the transaction, the president now owns 206,333 shares of the company’s stock, valued at $6,487,109.52. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Evolent Health news, President Daniel Joseph Mccarthy sold 1,000 shares of the business’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $31.44, for a total value of $31,440.00. Following the transaction, the president now owns 206,333 shares of the company’s stock, valued at $6,487,109.52. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Diane Holder sold 12,000 shares of the business’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $31.26, for a total value of $375,120.00. Following the completion of the transaction, the director now directly owns 60,140 shares in the company, valued at approximately $1,879,976.40. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 160,474 shares of company stock valued at $4,804,088. 3.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on EVH shares. StockNews.com started coverage on Evolent Health in a research report on Thursday, May 18th. They set a “sell” rating for the company. Guggenheim reiterated a “buy” rating and set a $47.00 price target on shares of Evolent Health in a report on Monday, August 14th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $46.56.

Evolent Health Company Profile

Evolent Health, Inc, a healthcare company, through its subsidiary, Evolent Health LLC, offers clinical and administrative solutions to payers and providers in the United States. The company operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management.